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Background: Neuroendocrine tumor (NET) of the thyroid other than medullary carcinoma is extremely rare. We
describe here a case of calcitonin-negative small cell neuroendocrine carcinoma (SCNEC), which occurred in a
thyroid gland that had previously been irradiated at high dose (60Gy) for pharyngeal cancer, with molecular
analyses for follicular cell origin.
Patient Findings: The tumor cells were small with fine chromatin, inconspicuous nucleoli, and inapparent cyto-
plasm, and showed neuroendocrine architectures such as palisading, rosettes, and trabeculae. Mitotic figures were
numerous exceeding 10 mitoses per 10 high-power fields. The tumor cells invaded into several vessels and metas-
tasized to regional lymph nodes. Immunohistochemically, the tumor cells were strongly positive for neuroendocrine
markers and thyroglobulin (Tg), a marker of thyroid follicular cells but negative for calcitonin and carcinoembryonic
antigen (CEA). Expression of Tg and thyrotropin receptor (TSHR) were confirmed by quantitative real-time poly-
merase chain reaction (RT-PCR). Ki-67 labeling index was more than 70% in the tumor cells. Taken together, the
tumor was diagnosed as SCNEC of the thyroid. Genetic analyses also revealed microsatellite abnormalities of the
phosphatase and tensin homolog (PTEN) gene, suggesting that functional loss of PTEN contributes to carcinogenesis.
Conclusions: This is the first report describing a SCNEC of the thyroid with molecular analyses that provide evidence
for a follicular epithelial origin.
Introduction
Thyroid cancer risk after exposure to ionizing radiationis of public concern. Papillary thyroid carcinoma (PTC) is
well known as the principal thyroid cancer cell type linked to
radiation, especially after childhood exposure (1). The histo-
logical type of thyroid cancer associated with therapeutic
external radiation exposure is most commonly PTC (2).
Anaplastic transformation of PTC is also rarely induced by
internal radiation with 131I after resection surgery for a pri-
mary tumor (3). We describe here a case of calcitonin-negative
small cell neuroendocrine carcinoma (SCNEC) that occurred
in a thyroid gland that had previously been irradiated at a
high dose for pharyngeal cancer.
Neuroendocrine tumor (NET) of the thyroid other than
medullary thyroid carcinoma (MTC), which is calcitonin
positive, is extremely rare, and only one case of calcitonin-
negative NET of the thyroid has previously been reported (4).
That case was not associated with any history of radiation ex-
posure and was histologically of the well-differentiated type, in
which absence of mitotic activity, vascular invasion, and ne-
crosis were noted. This is the first report describing a high-grade
NET of the thyroid with molecular analyses with evidence of a
thyroid follicular cell origin, and with alterations of the phos-
phatase and tensin homolog (PTEN) tumor suppressor gene.
Case Presentation
A 64-year-old Japanese male noticed a cervical mass. He
was an ex-smoker of 30 cigarettes per day for 20 years. His
family history did not include any endocrine disorders or any
cancer syndromes. However, the patient had a past history of
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three primary cancers other than thyroid gland including
esophageal cancer 18 years ago, squamous cell carcinoma of
the lower pharynx 10 years ago, and moderately differenti-
ated adenocarcinoma of the stomach 3 years ago. Surgical
resections were performed for the esophageal and gastric
cancers and no recurrence was evident so far. For the pha-
ryngeal cancer, the patient underwent total resection of both
the lower pharynx and larynx combined with left hemi-
thyroidectomy and reconstruction by jejunal interposition.
After the latter resection, he also received 60 Gy of external
irradiation to the whole neck. One year before noticing his
cervical mass, squamous cell carcinoma had recurred at his
upper pharynx, which was treated by endoscopic mucosal
resection, followed by 35 Gy of local external irradiation and
chemotherapy with 5FU and CDDP.
Examination of the cervical mass by magnetic resonance
imaging (MRI) disclosed a right thyroid mass and multiple
swollen lymph nodes in the paratracheal and superior me-
diastinum, suggesting thyroid cancer (Fig. 1). Fine-needle
aspiration was carried out, which showed malignant cells
suspicious for undifferentiated carcinoma. Preoperatively, he
was found to be profoundly hypothyroid: thyrotropin (TSH)
404.1 lIU/mL, free thyroxine (FT4) 0.13 ng/mL, free triiodo-
thyronine (FT3) 0.30 pg/mL, and thyroglobulin (Tg) 215.9 ng/
mL. The measurements of calcitonin and parathyroid hor-
mone were not preoperatively performed. He subsequently
underwent right thyroidectomy with dissection of the lymph
nodes to remove the thyroid mass, which measured 5.4 cm ·
2.7 cm · 1.9 cm, that occupied the right lobe of the thyroid
gland (Fig. 1). He had no clinical evidence of tumor recurrence
at the 1-year follow-up examination.
Pathologic Findings
The resected right thyroid gland was replaced by tumor
cells and demonstrated few remaining nontumorous thyroid
follicles. Tumor showed nested/nodular growth pattern with
occasional foci of comedo-like necrosis, which was separated
by fibrovascular stroma (Fig. 2). Neuroendocrine architec-
tures, such as palisading, rosettes, and trabeculae, were
clearly observed in the tumor nests (Fig. 2). The tumor cells
were small in size ( < 3 lymphocytes) and oval to polygonal in
shape with fine chromatin, inconspicuous nucleoli, and in-
apparent cytoplasms (Fig. 2). Mitotic figures were numerous
exceeding 10 mitoses per 10 high-power fields (Fig. 2). Tumor
cells invaded into several vessels and metastasized to regional
lymph nodes. The pathologic tumor stage was pT3N1bM0.
Immunhistochemical Profiles
Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded (FFPE) tissue sections from the resected
thyroid tumor. Antibodies used in this study are shown in
Supplementary Table S1 (Supplementary Data are available
online at www.liebertpub.com/thy). The immunohistochemi-
cal results are detailed in Table 1 and depicted in Figure 3,
respectively. It was observed that the tumor cells were positive
for neuroendocrine markers, such as synaptophysin and CD56,
and weakly positive for chromogranin A. Further, the staining
was strongly positive for thyroglobulin but negative for thyroid
FIG. 1. Magnetic resonance imag-
ing (A, B) and macroscopic view (C,
D) of the right thyroid tumor. The
patient had received postsurgical
treatment for pharyngeal cancer,
including total resection of both the
lower pharynx and larynx com-
bined with left hemithyroidectomy
and reconstruction by jejunal inter-
position.
594 MUSSAZHANOVA ET AL.
transcription factor-1 (TTF-1), both of which are markers of
thyroid follicular cell. Immunoreactivity for calcitonin and
carcinoembryonic antigen (CEA) was not observed in the tumor
cells. The tumor was also weakly positive for p53, and Ki-67
labeling index was more than 70% in the tumor cells (Supple-
mentary Fig. S1).
Molecular Analyses
Expression of TTF-1, Tg, and TSH receptor
by quantitative real-time RT-PCR
Total RNA was extracted from FFPE tissues of the present
case and two cases of PTC as well as their corresponding normal
thyroid tissues, which acted as positive controls, using the High
Pure RNA Paraffin Kit (Roche, Mannheim, Germany) according
to the manufacturer’s protocol. The cDNA was generated with
the SuperScript III First Strand Synthesis SuperMix (Invitrogen,
Carlsbad, CA) and analyzed by quantitative real-time poly-
merase chain reaction (RT-PCR) using Sybr Premix ExTaq qPCR
primer assays (Takara Bio, Shiga, Japan) and the Thermal Cycler
Dice Real Time multicolor PCR detection system (Takara, Shi-
zuoka, Japan). The primers used in this study are summarized
in Supplementary Table S2. Amplicons were designed to span
introns to exclude genomic DNA contamination. PCR products
were separated on 1% agarose gels and visualized by ethidium
bromide staining (Fig. 4A). These assays demonstrated the ex-
pressions of both TSH receptor and Tg, but not of TTF-1, in the
present case at the transcript level. All three genes were ex-
pressed by the two cases of PTC and/or their corresponding
nontumor part of thyroid tissues.
Analysis for RET/PTC rearrangements
and BRAFV600E mutations
Expression of RET/PTC1 and RET/PTC3 genes were as-
sessed by RT-PCR as described in a previous report (5). Nei-
ther RET/PTC1 nor RET/PTC3 was demonstrated in the
present case. Furthermore, tumor DNA was amplified to
generate products covering the common mutational hotspots
of BRAF, including a portion of exon 15 and and sequenced on
an ABI PRISM 3130 automated capillary DNA Sequencer
(Applied Biosystems) using the BigDye Terminator Cycle
Sequencing Ready Reaction Kit version 3.1 (Applied Biosys-
tems). No BRAF mutations were detected in the present case.
Loss of heterozygosity analysis of the phosphatase
and PTEN tumor suppressor gene
Using a Tissue Mini DNA Purification Kit (Epicentre Bio-
technologies), genomic DNA was extracted from FFPE tissues
FIG. 2. Histology of the
present thyroid tumor. The
tumor showed nested/
nodular growth pattern with
occasional foci of comedo-like
necrosis (A, original magnifi-
cation · 100) and occasional
invasion into vessels
(B, · 100). Neuroendocrine
morphology, such as pali-
sading, rosettes, and trabecu-
lae, was apparently observed
in the tumor nests, which
were separated by delicate
fibrovascular stroma
(C, · 200). The tumor cells
were small in size and oval to
polygonal in shape with fine
chromatin, inconspicuous
nucleoli, and inapparent cy-
toplasm (D, · 400). Numerous
mitotic figures were observed
(D).
Table 1. Immunohistochemical Results













p53 + / -
Ki67 LI 70%
a + + , positive cells > 60%; + , 30%*60%; + / - , 5*30%; - , < 5%.
CEA, carcinoembryonic antigen; TTF-1, thyroid transcription
factor-1; LI, labeling index.
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of both the tumor and its corresponding lymph node without
metastasis from the present case as well as a case of MTC and
a case of colonic NEC, which were used for loss of heterozy-
gosity (LOH) analysis by PCR. PCR reactions were routinely
performed in a final volume of 25 lL containing 10 ng of
sample DNA with the hot start ExTaq polymerase (Takara).
Five microsatellite markers were used to determine LOH in
the 10q23 region and its flanking polymorphic genetic
markers as described in a previous report (6). PCR was per-
formed under the following conditions: initial denaturation at
95C for 5 minutes followed by 37 cycles of amplification
(94C for 30 seconds, 56C for 30 seconds, and 72C for 30
seconds), and a final extension at 72C for 10 minutes, fol-
lowed by a 4C cooling step. Aliquots of the PCR products
were electrophoresed on 12% denaturing polyacrylamide gels
at 50V for 24 hours. After electrophoresis, the allelic band
intensity was detected using a commercially available ethi-
dium bromide solution, and was captured and analyzed us-
ing a BioDoc-It Imaging System (UVP, Inc., Upland, CA).
LOH was scored when the intensity of one allele was absent or
at least 75% reduced in the tumor alleles compared to the
corresponding wild-type alleles in the normal tissue.
The present case showed microsatellite abnormalities in
three of the five markers, including a biallelic loss at D10S541
and two monoallelic losses (LOH) at D10S2491 and D10S583,
while neither thyroid medullary carcinoma nor colonic neu-
roendocrine carcinoma showed any microsatellite abnormal-
ities in the five markers (Fig. 4B).
Discussion
This article describes a case of SCNEC of the thyroid that
occurred in a patient who had a past history of radiation ther-
apy for hypopharyngeal cancer. In the thyroid gland, although
MTC is well known as a NET arising from the calcitonin-pro-
ducing parafollicular cells (C-cells) that accounts for up to 10%
of all thyroid cancers, only one case of calcitonin-negative
FIG. 3. Immunohistochemistry for synaptophysin (A), chromogranin A (B), CD54 (C), thyroglobulin (D), thyroid tran-
scription factor (TTF)-1 (E), and cytokeratin 7 (F) in the present case (original magnification: · 200).
FIG. 4. (A) Reverse transcriptse polymerase chain reaction
(RT-PCR) analyses for thyroid transcription factor (TTF)-1,
thyroid stimulating hormone (TSH) receptor, and thyro-
globulin in the present case with two cases of papillary
thyroid carcinomas as control subjects (PTC1 and PTC2) (T,
tumor; N, its corresponding normal thyroid). (B) Loss of
heterozygosity (LOH) analysis of the phosphatase and tensin
homolog (PTEN) gene. The present case showed micro-
satellite abnormalities in three of the five markers, including
a biallelic loss at D10S541 and two monoallelic losses at
D10S2491 and D10S583, while neither thyroid medullary
carcinoma (MC) nor colonic neuroendocrine carcinoma
(NEC) showed any microsatellite abnormalities in these
markers.
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nonmedullary NET has previously been reported, which ex-
pressed Tg, synaptophysin, and chromogranin A, but not cal-
citonin by immunostaining, indicating a follicular cell origin (4).
In the present case, the expression of three markers of neuro-
endocrine differentiation, but not of calcitonin nor CEA, were
demonstrated. We also confirmed the expression of thyrotropin
receptor (TSHR) and Tg at the transcription level, providing
further evidence for a follicular cell origin of this tumor.
The expression of TTF-1 was not detected in the present
case at both mRNA and protein levels. TTF-1 expression is
highly restricted to epithelial tumors arising in the thyroid
and lung. Among pulmonary NETs, it has been documented
that TTF-1 expression is found in 35–50% of typical carcinoids,
100% of atypical carcinoids, 50% to 75% of large cell neuro-
endocrine carcinomas, and 81% to 95% of small cell carcino-
mas (7–9). Among thyroid NETs, MTCs seem to consistently
express TTF-1 (7,10), which is plausible because this protein
is expressed in C-cells (11,12). TTF-1 is a homeodomain-
containing transcriptional factor that binds to and activates
the promoters of thyroid-specific genes including TSHR, Tg,
and thyroid peroxidase genes in follicular cells (13). Therefore,
during carcinogenesis of SCNEC of the thyroid, the TTF-1
gene may be truncated, and the expression of some thyroid-
specific genes, such as TSHR and Tg, may be regulated in a
TTF-1 independent manner.
NETs may arise in most organs of the body and share many
common pathologic features. The 2004 World Health Orga-
nization (WHO) classification recognizes four major types of
lung NETs: low grade/typical carcinoid, intermediate grade/
atypical carcinoid, high grade/large cell neuroendocrine
carcinoma, and small cell lung cancer (14). More recently,
according to the 2010 WHO classification scheme, gastro-
enteropancreatic (GEP)-NETs are separated into well-
differentiated NETs and poorly differentiated NECs of the
small or large cell type (15). They are also divided according to
a grading system, which is based on the Ki67 proliferation
index or mitotic count. According to these criteria, the present
case is a high-grade (G3) NEC of small cell type. To the best of
our knowledge, this is the first report of SCNEC of the thyroid
in the English literature. Because the patient received external
radiation therapy to the whole neck for hypopharyngeal
cancer 10 years prior to the diagnosis of thyroid cancer, a
radiation etiology is suspected for this tumor. Although pre-
vious reports on postradiation small cell carcinoma are ex-
tremely rare, a case of secondary SCNEC of the cervix after
radiotherapy for cervical squamous cell carcinoma has been
documented (16). Radiation is a well-recognized risk factor in
thyroid carcinogenesis, and it is typically associated with
PTC. Therapy-related high-dose radiation might be able to
induce rare types of thyroid cancer including SCNEC.
PTEN is a tumor suppressor gene that has been found to be
somatically deleted, mutated, and/or silenced in various
sporadically occurring cancers such as glioblastoma, malig-
nant melanoma, as well as thyroid, breast, endometrial, and
ovarian carcinomas (17–23). Functional inactivation of the
PTEN gene may occur through deletion, LOH, and other
mutations (24). In thyroid tumors, transcriptional silencing of
PTEN has been shown to be significantly associated with the
anaplastic subtype, suggesting that PTEN is involved in the
carcinogenesis of highly malignant or late-stage thyroid can-
cers (25). Although several studies suggest that aberrant
methylation of the PTEN promoter is an epigenetic mecha-
nism in inactivating this gene in thyroid tumors (26–29), LOH
of PTEN seems to be a common genetic event in SCNEC of the
lung and gastrointestinal tract (30). In our analysis, micro-
satellite abnormalities of the PTEN gene, including a billelic
and two monoallelic losses, were found in the present case but
in neither MTC nor colonic NEC. Thus, inactivation of the
PTEN gene is suggested to be involved in the carcinogenesis
of thyroid SCNEC, similarly to anaplastic thyroid cancers and
SCNECs found in other organs.
In summary, we describe a case of SCNEC of the thyroid,
which occurred in a patient who had received therapy-related
high dose irradiation. The findings suggest that the tumor was
of follicular origin. To the best of our knowledge, this is the
first report of calcitonin-negative high-grade NEC of the
thyroid.
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